Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells.
VEGF121 and VEGF165 are vascular endothelial growth factor splice variants that promote the proliferation of endothelial cells and angiogenesis. VEGF165 contains the 44 additional amino acids encoded by exon 7 of the VEGF gene. These amino acids confer upon VEGF165 a heparin binding capability which VEGF121 lacks. 125I-VEGF165 bound to three vascular endothelial growth factor (VEGF) receptors on endothelial cells, while 125I-VEGF121 bound selectively only to the flk-1 VEGF receptor which corresponds to the larger of the three VEGF receptors. The binding of 125I-VEGF121 to flk-1 was not affected by the removal of cell surface heparan sulfates or by heparin. Both VEGF165 and VEGF121 inhibited the binding of 125I-VEGF121 to a soluble extracellular domain of the flk-1 VEGF receptor in the absence of heparin. However, heparin potentiated the inhibitory effect of VEGF165 by 2-3-fold. These results contrast with previous observations which have indicated that the binding of 125I-VEGF165 to the flk-1 receptor is strongly dependent on heparin-like molecules. Further experiments showed that the receptor binding ability of VEGF165 is susceptible to oxidative damage caused by oxidants such as H2O2 or chloramine-T. VEGF121 was also damaged by oxidants but to a lesser extent. Heparin or cell surface heparan sulfates restored the flk-1 binding ability of damaged VEGF165 but not the receptor binding ability of damaged VEGF121. These observations suggest that alternative splicing can generate a diversity in growth factor signaling by determining receptor recognition patterns. They also indicate that the heparin binding ability of VEGF165 may enable the restoration of damaged VEGF165 function in processes such as inflammation or wound healing.
Gitay-Goren
H
H
Department of Biology, Technion, Israel Institute of Technology, Haifa 32000, Israel.
Cohen
T
T
Tessler
S
S
Soker
S
S
Gengrinovitch
S
S
Rockwell
P
P
Klagsbrun
M
M
Levi
B Z
BZ
Neufeld
G
G
D000818:Animals; D001667:Binding, Competitive; D002460:Cell Line; D002478:Cells, Cultured; D002700:Chloramines / Q000494:pharmacology; D004591:Electrophoresis, Polyacrylamide Gel; D016228:Endothelial Growth Factors / Q000302:isolation & purification / Q000378:metabolism* / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000378:metabolism*; D014644:Genetic Variation; D006493:Heparin / Q000494:pharmacology; D006497:Heparan Sulfate / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008222:Lymphokines / Q000302:isolation & purification / Q000378:metabolism* / Q000494:pharmacology*; D008970:Molecular Weight; D016877:Oxidants / Q000494:pharmacology; D010084:Oxidation-Reduction; D020794:Receptor Protein-Tyrosine Kinases / Q000302:isolation & purification / Q000378:metabolism*; D017978:Receptors, Growth Factor / Q000302:isolation & purification / Q000378:metabolism*; D040262:Receptors, Vascular Endothelial Growth Factor; D011994:Recombinant Proteins / Q000378:metabolism; D015398:Signal Transduction; D013329:Structure-Activity Relationship; D014105:Tosyl Compounds / Q000494:pharmacology; D014162:Transfection; D014471:Umbilical Veins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D002700:Chloramines; D016228:Endothelial Growth Factors; D006493:Heparin; D006497:Heparan Sulfate; D008222:Lymphokines; D016877:Oxidants; D020794:Receptor Protein-Tyrosine Kinases; D017978:Receptors, Growth Factor; D040262:Receptors, Vascular Endothelial Growth Factor; D011994:Recombinant Proteins; D014105:Tosyl Compounds; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C467484:VEGFA protein, human; C016300:chloramine-T